Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
SAN FRANCISCO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq:…
NABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMS
The MoU signed in 2022 has progressed and culminated in the subsumption of…
NABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMS
The MoU signed in 2022 has progressed and culminated in the subsumption of…
NABH INTEGRATES FOGSI’S MATERNAL HEALTH STANDARDS ACROSS ITS CERTIFICATION PROGRAMS
The MoU signed in 2022 has progressed and culminated in the subsumption of…
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 08, 2024 10:00 ET | Source: Medicenna Therapeutics Corp. MDNA113…